Hemab Therapeutics (NASDAQ:COAG) Raised to Strong-Buy at Rodman & Renshaw

Hemab Therapeutics (NASDAQ:COAG) was upgraded by research analysts at Rodman & Renshaw to a “strong-buy” rating in a research note issued to investors on Monday, Zacks reports.

Other equities research analysts have also issued reports about the stock. Weiss Ratings lowered shares of Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 25th. Jefferies Financial Group upped their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Wedbush increased their target price on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Finally, HC Wainwright increased their target price on Hemab Therapeutics from $52.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Hemab Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $52.17.

Hemab Therapeutics Stock Performance

Shares of Hemab Therapeutics stock opened at $29.80 on Monday. Hemab Therapeutics has a 12 month low of $23.00 and a 12 month high of $55.42. The business’s fifty day simple moving average is $42.06.

Hemab Therapeutics (NASDAQ:COAG) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). On average, analysts expect that Hemab Therapeutics will post -3.09 EPS for the current year.

Hedge Funds Weigh In On Hemab Therapeutics

Several hedge funds have recently made changes to their positions in COAG. Squarepoint Ops LLC acquired a new stake in shares of Hemab Therapeutics in the second quarter valued at approximately $230,000. The Manufacturers Life Insurance Company acquired a new position in Hemab Therapeutics during the second quarter worth $688,000. Opaleye Management Inc. acquired a new position in Hemab Therapeutics during the second quarter worth $1,750,000. State Street Corp acquired a new position in Hemab Therapeutics during the second quarter worth $2,825,000. Finally, Braidwell LP bought a new position in Hemab Therapeutics in the second quarter valued at $5,877,000.

About Hemab Therapeutics

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.